Eszter Kozak

Ms. Eszter Kozak

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2021 in Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
EKEszter Kozak
Eszter Kozak
KFKrisztina Fülöp
Krisztina Fülöp
NTNatália Tőkési
Natália Tőkési
NRNidhi Rao
Nidhi Rao
QLQiaoli Li
Qiaoli Li
VPViola Pomozi
Viola Pomozi

29 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EKEszter Kozak
Eszter Kozak
JBjonas bartstra
jonas bartstra
Pim de JongPim de Jong
Pim de Jong
Willem . P.Th.M MaliWillem . P.Th.M Mali
Willem . P.Th.M Mali
KFKrisztina Fülöp
Krisztina Fülöp
WSWilko Spiering
Wilko Spiering
Background: Pseudoxanthoma elasticum (PXE), a monogenic disorder resulting in calcification affecting the skin, eyes and peripheral arteries, is caused by mutations in the ABCC6 gene, and is associated with low plasma inorganic pyrophosphate (PPi). It is unknown how ABCC6 genotype affects plasma PPi. Methods: We studied the association of ABCC6 genotype (192 patients with biallelic pathogenic ABCC6 mutations) and PPi levels, and its association with the severity of arterial and ophthalmological phenotypes. ABCC6 variants were classified as truncating or non-truncating, and three groups of the 192 patients were formed: those with truncating mutations on both chromosomes (n = 121), those with two non-truncating mutations (n = 10), and a group who had one truncating and one non-truncating ABCC6 mutation (n = 61). The hypothesis formulated before this study was that there was a negative association between PPi level and disease severity. Results: Our findings confirm low PPi in PXE compared with healthy controls (0.53 ± 0.15 vs. 1.13 ± 0.29 µM, p < 0.01). The PPi of patients correlated with increasing age (β: 0.05 µM, 95% CI: 0.03–0.06 per 10 years) and was higher in females (0.55 ± 0.17 vs. 0.51 ± 0.13 µM in males, p = 0.03). However, no association between PPi and PXE phenotypes was found. When adjusted for age and sex, no association between PPi and ABCC6 genotype was found. Conclusions: Our data suggest that the relationship between ABCC6 mutations and reduced plasma PPi may not be as direct as previously thought. PPi levels varied widely, even in patients with the same ABCC6 mutations, further suggesting a lack of direct correlation between them, even though the ABCC6 protein-mediated pathway is responsible for ~60% of this metabolite in the circulation. We discuss potential factors that may perturb the expected associations between ABCC6 genotype and PPi and between PPi and disease severity. Our findings support the argument that predictions of pathogenicity made on the basis of mutations (or on the structure of the mutated protein) could be misleading.

28 April 2025 in ACR Open Rheumatology
Verified
Journal Article
Open access
GBGergely Bodor
Gergely Bodor
MBMárta Bocskai
Márta Bocskai
ÁDÁgnes Dura
Ágnes Dura
LKLászló Kovács
László Kovács
AVAndrás Váradi
András Váradi
EKEszter Kozak
Eszter Kozak
Objective: Calcinosis is a manifestation of systemic sclerosis with a severe negative impact on quality of life. Efforts to find a treatment for calcinosis have been hindered by our limited understanding of the underlying pathomechanism. We propose that extracellular pyrophosphate deficiency may have a causal role in the formation of these mineralized deposits, because pyrophosphate inhibits the deposition of hydroxyapatite—the major constituent of calcinosis—and supplementing pyrophosphate may have therapeutic potential in the treatment of calcinosis.Methods: Systemic sclerosis patients were treated with a single dose of 50 mg/kg disodium pyrophosphate (cohort 1, n = 10), or a daily dose of 25 mg/kg disodium pyrophosphate for seven consecutive days (cohort 2, n = 10). Safety of oral pyrophosphate treatment was assessed with special focus on gastrointestinal tolerance, serum phosphate and calcium levels, and potential electrocardiography abnormalities. Absorption kinetics and peak plasma pyrophosphate concentrations were measured by the adenosine triphosphate sulfurylase method.Results: Gastrointestinal adverse effects associated with oral pyrophosphate treatment were rare and mild. The only consistent abnormality among the serum parameters studied was a transient elevation of serum phosphate levels (change: 0.2 to 0.62 and 0.15 to 0.44 mmol/L in cohorts 1 and 2, respectively). Based on electrocardiography results, both doses can be regarded as safe in terms of corrected QT interval prolongation in short‐term treatment. Serum pyrophosphate levels increased significantly in both cohorts.Conclusion: Oral pyrophosphate treatment was found to be safe in patients with systemic sclerosis and resulted in elevated plasma concentrations comparable to results obtained in healthy volunteers. This provides rationale to test the therapeutic potential of pyrophosphate against calcinosis.